Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner Sobi
31.10.2023 - WATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) - Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, ... Seite 1
Source: wallstreet-online.de